Literature:

​

Germain D P, Fabry disease, OJRD (2010), 5:30

​

Ortiz A at al, Fabry disease revisited: Management and treatment recommendations for adult patients, Mol Genet Metab 123 (2018): 416–427

​

Wanner C et al, European expert consensus statement on therapeutic goals in FD, Mol Genet Metab 124 (2018): 189-203

​

Kok K et al, Fabry Disease:Molecular Basis Pathophysiology Diagnostics and Potential Therapeutic Directions, Biomolecules (2021): 11, 271

​

Germain D P et al, An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease Mol Genet Metab  (2022): 137, 49-61

​

Feriozzi S et al., The inflammatory pathogenetic pathways of Fabry nephropathy, Rare Dis Orphan Drugs J (2024); 3: 11

​

Feriozzi S et al., Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with FD: Insights from Real-World Data, DDDT (2024):18, 1083–1101

​

Pieroni M et al, Anderson-Fabry disease management: role of the cardiologist, Eu Heart J (2024): 45, 1395–1409

​